All In Biotech

Drug Trial Radar · NCT06109779

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 760 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

760

Actual

Start

Dec 4, 2023

Primary completion

Jan 2, 2029

Study completion May 3, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Conditions

  • Biliary Tract Cancer

Interventions

  • RilvegostomigDrug

    Rilvegostomig IV (intravenous) Q3W

  • PlaceboDrug

    Placebo IV (intravenous) Q3W

  • CapecitabineDrug

    Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice

  • Gemcitabine/CisplatinDrug

    Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle

  • S-1 [Tegafur/Oteracil/gimeracil]Drug

    S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence free survival (RFS) for Arm A vs. Arm BTime frame: Approximately 5 years

Locations

176 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    Stanford, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Littleton, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Jacksonville, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Iowa City, Iowa

  • Research Site

    Kansas City, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Commack, New York

  • Research Site

    Mineola, New York

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Dallas, Texas

  • Research Site

    Camperdown, Australia

  • Research Site

    Clayton, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    Westmead, Australia

  • Research Site

    Brussels, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Natal, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Santa Maria, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Vitória, Brazil

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.